Jeffrey Hubbell is a highly experienced researcher in the field of molecular bioengineering, with research foci in regenerative medicine and engineering immunity. Trained as a chemical engineer, he utilizes biomaterials engineering and protein engineering methodology to engineer growth factor/ extracellular matrix therapeutics in regenerative medicine as well as to engineer nanoparticle vaccines, tolerogenic (inverse) vaccines and targeted drug delivery vehicles. In the context of immunoengineering, he has developed novel technology by which to target antigens that are resident in the lymph nodes that drain the injection site. In work funded by the Gates Foundation, applications have focused on influenza and tuberculosis. In other work, application has focused on cancer vaccination. In the field of immunological tolerance induction, his laboratory has developed technology to target cell populations in the liver by targeting those antigens to the surfaces of erythrocytes after injection. He has also developed glycopolymer technology to target liver cell populations through the asialoglycoprotein receptor, among other receptors. He has been active in technology transfer, having had one technology to enter a variety of clinical products (through a start-up Focal Inc., now a part of Sanofi-Aventis, Focal having been acquired by Genzyme), another that has been in >500 patients in clinical trials and is still in clinical development (through a start-up Kuros Biosurgery, Zurich), and two others that are currently in non-human primate testing in preclinical development in the field of immunological tolerance (thorough Anokion, located in Lausanne, Switzerland and Cambridge, MA, and Kanyos Bio, located in Cambridge, MA). He has spent the years of 1997/2014/16 in Switzerland, with a position from 2003 as Professor of Bioengineering and Chemical Engineering at the Ecole Polytechnique Fédérale de Lausanne (EPFL). While in Lausanne, Prof. Hubbell was founding Director of the Institute for Bioengineering and later Dean a.i. of the School of Life Sciences. In Summer 2014, he transitioned from the EPFL to the University of Chicago. At the University of Chicago, his primary academic appointment is in the Institute for Molecular Engineering, a newly established endeavor to develop novel molecular technologies in biomedicine, materials, energy, quantum computing, and water resources, among other, with nanotechnology being of particular importance in all aspects of the Institute. He is also a full member of the University’s Committee on Immunology, which functions as an interdepartmental immunology center.